ImmuneTier 3 β Animal + early human data
Thymopentin
TP-5 Β· Timunox Β· Thymic Pentapeptide
Synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) corresponding to the active site of thymopoietin. Restores T-cell differentiation and immune balance in immunodeficiency states. Widely used in China and Italy.
π SC injection / IM injectionπ§ Lyophilised: refrigerate; reconstituted: use within 7 days refrigerated.
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Binds the thymopoietin receptor on T-cell precursors, inducing maturation of immature thymocytes into functional T-helper and T-suppressor cells. Restores CD4/CD8 ratio, upregulates IL-2 receptor expression, and normalises Th1/Th2 balance. Shorter and less potent than Thymosin Alpha-1 but faster onset (hours) due to small size.
Clinical Applications
- βRecurrent upper respiratory tract infections and chronic sinusitis
- βPost-antibiotic immune recovery
- βAge-related immunosenescence
- βAdjuvant in chronic hepatitis B (Asian clinical data)
- βChemotherapy-induced lymphopenia support
- βAllergy and atopic conditions (Th1/Th2 rebalancing)
Dosing Protocol
Recommended Dosing
SC or IM injection. 1 mg daily for 5β10 days (acute protocol). Maintenance: 1 mg 2β3Γ weekly for 4β8 weeks. Often run as a series of 1β2 courses per year. Well tolerated at these doses; no dose-finding studies beyond 1 mg.Safety & Contraindications
Possible Side Effects
- β Injection site reactions (mild)
- β Occasional transient fatigue
- β Generally very well tolerated β better than TA-1 for injection site reactions
Contraindications
- βOrgan transplant recipients on immunosuppression
- βPregnancy
- βActive autoimmune disease β same caution as Thymosin Alpha-1
Combinations & Synergies
π Thymosin Alpha-1complementary immune restoration (TA-1 for adaptive, TP-5 for rapid innate/T-precursor effect)
π LL-37innate + adaptive immune breadth
π BPC-157gut-immune axis, especially post-antibiotic